TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients who fulfil ALL the following criteria are included.~1. Patients who diagnosed with COPD who were prescribed with LABA/LABA (FDC or free combo) as a new initiation or switching from other therapy (i.e., single/dual/triple), or newly receiving LAMA treatment for 3 months at least prior to 30 June 2018~2. Male or female patients ≥ 40 years of age~Exclusion Criteria:~1. Patients who meet the following criterion are not included.~* Patients with documented diagnosis of bronchial asthma, asthma-COPD overlap syndrome (ACOS), bronchiectasis, cystic fibrosis, or lung cancer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with Tiotropium and Olodaterol (Type: None): None
- Subjects treated with other LABA/LAMA therapy (Type: None): None
- Subjects treated with LAMA therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren for Immunoglobulin A (IgA) Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18-65 years~* requires anti-hypertensive therapy~* renal biopsy within the past 3 years and confirmed the diagnosis of IgA nephropathy~* proteinuria \> 1 g/day (or proteinuria \> 1 g/g-Cr) in 3 consecutive samples within 12 weeks despite ACE inhibitor or ARB treatment for at least 3 months~* estimated glomerular filtration rate \> 30 ml/min/1.73m2~* willingness to give written consent and comply with the study protocol~Exclusion Criteria:~* Patients who are diabetic, and patients with systemic diseases that may cause IgA nephropathy or another nephropathy.~* Pregnancy, lactating or childbearing potential without effective method of birth control~* Severe gastrointestinal disorders that interfere with their ability to receive or absorb oral medication~* History of malignancy, including leukemia and lymphoma within the past 2 years~* Systemic infection requiring therapy at study entry~* Any other severe coexisting disease such as, but not limited to, chronic liver disease, myocardial infarction, cerebrovascular accident, malignant hypertension~* History of drug or alcohol abuse within past 2 years~* Participation in any previous trial on aliskiren or other renin inhibitor~* Previous treatment with fish oil, steroid, cytotoxic agents, or aldosterone antagonist~* History of treatment with other drugs that may affect proteinuria within past 2 years~* Patients receiving treatment of corticosteroid~* On other investigational drugs within last 30 days~* History of a psychological illness or condition such as to interfere with the patient's ability to understand the requirement of the study~* History of non-compliance~* Known history of sensitivity or allergy to aliskiren or other renin inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
- II (Type: ACTIVE_COMPARATOR): each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Propofol Dose Finding Study In Neonates

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates admitted to the Neonatal Intensive Care Unit who need short procedural sedation for (semi-) elective intubation will be considered for inclusion, after informed written consent of the parents.~* Patients can be included if they are hemodynamically stable and did not receive sedative or analgesic agents during the previous 24 hours.~Exclusion Criteria:~* Known propofol intolerance

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- propofol (Type: OTHER): All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Post-Stroke Upper Extremity Assistance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* greater than 6 months post-stroke~* passive abduction to 90 degrees at shoulder~* reduced active (retro)flexion/extension at shoulder when abducted at 90 degrees~* reduced active flexion/extension at elbow~Exclusion Criteria:~* unable to give informed consent~* unable to comprehend and follow instructions~* have a condition (other than stroke) affecting sensorimotor function~* show evidence of unilateral spatial neglect~* unable to sit in a chair without armrests for 2 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stroke Survivors (Type: EXPERIMENTAL): Stroke survivors with upper extremity motor impairments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be 18 years of age or older.~* If female, subject is either not of childbearing potential, defined as postmenopausal for at least one year or surgically sterile, or is of childbearing potential and must agree to practice birth control for the duration of the study.~* Have dyslipidemia as demonstrated by laboratory results.~Exclusion Criteria:~* Have glycosylated hemoglobin (HbA1c) \>= 9.0%.~* Have nephrotic syndrome, dysproteinemias, or severe renal failure (glomerular filtration rate \[GFR\] \< 30 mL/minute, as calculated from creatinine clearance).~* Have had unstable angina or an acute myocardial infarction (MI) within three months of the Screening Visit.~* Have had severe peripheral artery disease as evidenced by intermittent claudication within three months of the Screening Visit.~* Have had uncontrolled cardiac arrhythmias within three months of the Screening Visit.~* Have symptomatic heart failure defined as dyspnea at rest or with exertion (mild peripheral edema is not exclusionary).~* Have a systolic blood pressure measurement of \> 180 mmHg or a diastolic blood pressure measurement of \> 110 mmHg at the Screening or Baseline Visit~* Have active gout or uric acid \>= 11 mg/dL.~* Have a history of hepatitis (acute or chronic), obstructive liver disease, or alanine aminotransferase (ALT; serum glutamic pyruvic transaminase \[SGPT\]) or aspartate aminotransferase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) values \>= 1.3 times the upper limit of normal (ULN) at the Screening Visit.~* Have creatine phosphokinase (CPK) \>= 3 x ULN at the Screening Visit.~* Have used an investigational study drug or participated in an investigational study within 30 days of the Screening Visit.~* Have a health condition or laboratory abnormality (inclusive of clinically significant laboratory results at Screening Visit), which, in the opinion of the Investigator, may be adversely affected by the procedures or study medications in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NER/ASA (Type: EXPERIMENTAL): None
- NER/ASA Placebo (Type: EXPERIMENTAL): None
- NER Placebo/ASA Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with coronary heart disease indicated for elective coronary artery bypass grafting under cardiopulmonary bypass~* Patients with left ventricle ejection fraction 31% -50% confirmed by echocardiography or radio nuclear study.~* Patients age ≥18 years~* Never had heart surgery before~* Agree to participate in the study and signed informed consent~Exclusion Criteria:~* Emergency coronary artery grafting bypass~* Having additional procedures other than coronary artery bypass grafting~* History of myocardial infarction with onset less than 3 months~* Patients with serum creatinine level more than 2 g/dL~* Patients with ALT/AST levels more than 1.5 times the upper limit of normal value~* Required to use intra-aortic balloon pump pre-operatively~* History of stroke with onset less than 3 months~* History of pre-operative atrial fibrillation~* History of heart conduction problem and/or using a pacemaker~* Patients with HIV~* Contraindications to pulmonary artery catheter insertion~Drop out Criteria~* Experiencing stroke after surgery~* Experiencing surgery related complication (haemorrhage) requiring re operation~* Requiring continuous veno-venous hemofiltration or haemodialysis after surgery~* Delayed sternal closure~* Aortic cross clamp duration more than 120 minutes and/or cardiopulmonary bypass time more than 180 minutes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glutamine (Type: EXPERIMENTAL): Intravenous L-alanyl-L-glutamine 0.5 mg/kgbw
- Control (Type: PLACEBO_COMPARATOR): Intravenous NaCl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
The key inclusion criteria are:~1. Male or female adult de novo kidney, kidney-pancreas or kidney-islet, or kidney-liver transplant recipients~2. Functioning graft within 28 days after transplantation (creatinine having decreased to \<200 micromol/l without the need for dialysis)~3. Being on standard triple immunosuppression including a calcineurin antagonist (cyclosporine or tacrolimus), mycophenolate (MMF or MPA) and steroids, with or without induction treatment with basiliximab or anti-thymocyte globulin~Key exclusion criteria are:~1. Age \<18 years~2. Rising creatinine after initial drop \<200 micromol/l or creatinine \>200 micromol/l at baseline~3. Evidence of early acute rejection, either suspected clinically and/or proven by biopsy~4. Presence of severe osteoporosis as evidenced by a T score \<-4 at the hip, femoral neck or any of the 4 vertebrae L1 to L4~5. Evidence of severe hyper- or hypoparathyroidism (iPTH \>800 ng/l or \<10 ng/l)~6. Hypocalcemia (total calcium \<1.8 mmol/l) or hypercalcemia (total calcium \>2.7 mmol/l)~7. Steroid-free de novo immunosuppression scheme

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): 60 mg denosumab s.c. at baseline and after 6 months
- Control (Type: NO_INTERVENTION): No treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Avalglucosidase Alfa Extension Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Participants with Pompe disease who previously completed an avalglucosidase study.~The participant and/or their parent/legal guardian is willing and able to provide signed informed consent, and the participant, if \<18 years of age, was willing to provide assent if deemed able to do so.~The participant (and participant's legal guardian if participant is \<18 years of age) must have had the ability to comply with the clinical protocol.~The participant, if female and of childbearing potential, had to have a negative pregnancy test \[urine beta-human chorionic gonadotropin\] at baseline.~Exclusion criteria:~The participant was concurrently participating in another clinical study using investigational treatment.~The participant, in the opinion of the Investigator, was unable to adhere to the requirements of the study.~The participant had clinically significant organic disease (with the exception of symptoms relating to Pompe disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, precluded participation in the study or potentially decreases survival.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avalglucosidase Alfa (Type: EXPERIMENTAL): administered intravenously every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Oral Contraceptives on Women Balance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women in group (A) had takenthe oral contraceptive pill have done so routinely for the past three months.~* All women in group (B) had a normal menstrual cycle; use any other non-hormonal contraceptive method.~* Their body mass index did not exceed 30 Kg/m2.~* All women had a normal menstrual cycle of 25-32 days for the past 3 months.~* They can stand independently.~Exclusion Criteria:~* Respiratory or heart problems.~* Skeletal deformityorusing assistive devices.~* Visual and vestibular system affection.~* Cognition problems.~* Previous surgeries at their back and/or lower limbs.~* Genital and breast cancer and active liver disease.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Oral contraceptive pills users (Type: ACTIVE_COMPARATOR): The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
- control (Type: NO_INTERVENTION): no drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~1. Not younger than 18 years of either sex~2. Health personnel from the Dr. Alberto Eurnekian Interzonal University Hospital~3. No COVID-19 related symptoms~4. Able to understand and give written informed consent~Exclusion criteria~1. Known hypersensitivity or allergy to any component of the product under evaluation~2. Age under 18 years~3. Use of immunosuppressants (including systemic corticosteroids) in the past 30 days.~4. Pregnant or nursing.~5. Patients with other acute infectious diseases.~6. Patients with autoimmune disease and / or decompensated chronic diseases.~7. Unable to fulfill the administrative tasks proposed by the study.~8. Infection with SARSCoV-2 confirmed by PCR or rapid test authorized by ANMAT.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IVER+ (Type: None): Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
- IVER- (Type: None): Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current anxiety or depression symptoms~* internet access~Exclusion Criteria:~* lifetime psychotic disorder, past-year substance dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Engaging computerized tasks (Type: ACTIVE_COMPARATOR): Participants will log into a personalized website and engage in computerized tasks online.
- Neurobehavioral computerized tasks (Type: EXPERIMENTAL): Participants will log into a personalized website and engage in computerized tasks online.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patient inclusion criteria:~* HIV-infected~* Receiving HIV care in the index clinic~* Age \>18 years old~* Meets criteria for lifetime or current tobacco, alcohol and/or opioid use disorder regardless of addiction treatment status~* Able to provide verbal informed consent~Staff inclusion criteria:~* Employed at participating HIV clinic for at least 6 months~* Able to provide verbal informed consent.~Payer/health insurance provider inclusion criteria:~* Employed at an organization or agency that provides funding for medical services for HIV-infected individuals for at least 6 months.~* Able to provide verbal informed consent.~Exclusion Criteria:~* Unable to provide verbal informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care- Control (Type: NO_INTERVENTION): We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
- Implementation Facilitation (Type: EXPERIMENTAL): We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete